Viewing records where tag name contains "news" View All

Second DEP™ candidate selected by AstraZeneca

Dec 2nd, 2015

Starpharma today announced that AstraZeneca has selected a second DEP™ candidate and Starpharma will now commence a new DEP™ project incorporating the second proprietary AstraZeneca oncology molecule.

Read More

EU Marketing Approval Granted for VivaGel® BV

Sep 24th, 2015

Starpharma today announced it has received, overnight, marketing approval in the European Union (EU) for VivaGel® BV for the treatment and rapid relief of bacterial vaginosis (BV) including symptoms.

Read More

Starpharma signs drug delivery license with AstraZeneca

Sep 7th, 2015

Starpharma today announced the signing of a licensing agreement with global pharmaceutical company AstraZeneca. The agreement enables the development and commercialisation by AstraZeneca of compounds directed at a defined family of targets using Starpharma’s DEP® drug delivery technology. The DEP® platform centres on use of Starpharma’s proprietary dendrimers, with the aim of enhancing the dosing and efficacy characteristics of pharmaceuticals.

Read More